Onkológia 4/2018
Glukokortikoidy v liečbe kastračne-rezistentného karcinómu prostaty a mechanizmy rezistencie na androgénnu blokádu
Glucocorticoids in the castrate-resistant prostate cancer treatment and mechanisms of androgen deprivation resistance
Androgens play an important role in the prostate carcinoma development. Its deprivation (ADT) in the form of castration (surgical or chemical) has been used in the treatment of this malignant cancer for almost 80 years. At some stage in the development of advanced cancer, the disease progresses despite castration levels of plasma testosterone. This is so called castrate-resistant prostate cancer (CRPC). Synthetic glucocorticoids are commonly used as CRPC therapeutic options in the combination with abiraterone and cytostatics (mitoxantrone, taxanes). However, several experimental and clinical studies demonstrated that concomitant use of the glucocorticoids with enzalutamide might induce resistance to this androgen receptor-targeted agent (ARTA).
Keywords: prostate cancer, androgen deprivation, resistance, glucocorticoids, enzalutamide












